Market cap
$113.4m
End-of-day close multiplied by current shares on issue.
RAD · NZX
Radius Residential Care is an NZX-listed healthcare / aged care company. Its latest covered result is HY27, with FY23 - HY27 of source-backed result history on Annolyse.
Latest result
HY27, released 11 November 2026
| Metric | Value | Change |
|---|---|---|
| Revenue | $108.6m | ↑ +8.4% |
| EBITDA | $16.6m | ↑ +11.2% |
| NPAT | $8m | ↑ +27.3% |
| Operating cash flow | $6.5m | ↓ -51.1% |
| OCF / EBITDA % | 39.3% | ↓ -50.0pp |
| Net debt | $90.5m | ↑ +42.2% |
| Net debt / EBITDA | 5.46x | ↑ +27.9% |
| ROE % | 9.8% | ↑ +0.7pp |
| DPS | 1.1c | ↑ +10.0% |
| Payout ratio vs NPAT % | 38.9% | ↓ -5.9pp |
Source: latest published briefing (HY27, released 11 November 2026). Change compares against the prior equivalent period: HY26, released 19 November 2025.
Valuation
Trailing P/E, EV/EBITDA, price-to-book and price-to-free-cash-flow ratios combine the latest available close with filing data. They are comparative measures, not forecasts or recommendations.
The latest close and share count context for the market price.
Market cap
$113.4m
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
10.1x
Recent market cap compared with trailing earnings.
EPS
0.04
Recent filing-derived earnings per share.
PEG
0.38x
P/E compared with recent earnings growth.
EV/EBITDA
7.02x
Enterprise value compared with recent EBITDA.
P/FCF
Not available
Not meaningful when free cash flow is negative or unavailable.
P/B
1.39x
Market value compared with latest reported equity.
Yield and investment-company valuation where supported.
Dividend yield
5.5%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Daily closes use the full available width, with hover and touch values for each observation. Expand the chart to see more detail.
Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.
Filing-period markers only: EOD close on or before each release date divided by filing-derived trailing NPAT where both inputs verify.
Chat
Ask follow-up questions about Radius Residential Care's latest result and company history.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Financial history
The latest period is shown first.
| Metric | HY276 MONTHS11 November 2026 | FY2612 MONTHS13 May 2026 | HY266 MONTHS19 November 2025 | FY2512 MONTHS21 May 2025 | HY256 MONTHS25 November 2024 | FY2412 MONTHS29 May 2024 | HY246 MONTHS27 November 2023 | FY2312 MONTHS29 May 2023 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $108.6m | $200.1m | $100.2m | $175.3m | $85.4m | $168.7m | $83.3m | $146.3m | Chart |
| Revenue growth % | 8.4% | 14.2% | 19.0% | 3.9% | 2.5% | 15.4% | 19.2% | 10.8% | Chart |
| EBITDA | $16.6m | $27.4m | $14.9m | $23.5m | $9.6m | $20.9m | $10.5m | $14.2m | Chart |
| EBITDA margin % | 15.3% | 13.7% | 14.9% | 13.4% | 11.3% | 12.4% | 12.5% | 9.7% | Chart |
| PBT | $10m | $14.3m | $8.5m | $10.5m | $2.8m | $3.6m | $1.6m | -$3m | Chart |
| PBT growth % | 17.3% | 36.2% | 203.6% | 191.7% | 75.0% | — | -27.3% | — | Chart |
| NPAT | $8m | $9.5m | $6.3m | $7m | $2m | -$8.5m | $1.4m | -$2.1m | Chart |
| NPAT growth % | 26.7% | 35.7% | 215.0% | — | 42.9% | — | -17.6% | — | Chart |
| Operating cash flow | $6.5m | $25.1m | $13.3m | $20.1m | $6.6m | $14.1m | $5.6m | $4m | Chart |
| OCF / EBITDA % | 39.3% | 91.8% | 89.3% | 85.4% | 68.5% | 67.4% | 53.6% | 28.4% | Chart |
| FCF pre-lease | $0.44m | $9m | $9.6m | $13.7m | $3.7m | $10.6m | $3.7m | -$54.6m | Chart |
| DPS | 1.1c | 1.2c | 1.0c | 0.8c | 0.7c | 0.7c | 0.0c | — | Chart |
| Payout ratio vs NPAT % | 38.9% | 66.1% | 44.8% | 55.8% | 94.2% | — | — | — | Chart |
| Annual payout ratio vs EPS % | — | 66.1% | — | 55.8% | — | — | — | — | Chart |
| ROE % | 9.8% | 12.4%Outside range high roe. 12.4%; 3-period range -13.2% to 10.6%. ROE: 12.4%, above normal range; 3-period mean -1.8%, range -13.2%-10.6%. | 9.1% | 10.6% | 3.1% | -13.2% | 1.9% | -2.9% | Chart
|
| Net debt | $90.5m | $68.7m | $63.7m | $67.7m | $73.2m | $73.5m | $96.8m | $100.1m | Chart |
| Net debt / EBITDA | 5.46x | 2.51x | 4.27x | 2.89x | 7.59x | 3.51x | 9.26x | 7.05x | Chart |
| Debtor days | 24 | 21Outside range low debtor days. 21d; 3-period range 24d to 33d. Debtor days: 21.2 days, below normal range; 3-period mean 27.4 days, range 24.0 days-32.6 days. | 23 | 24 | 26 | 26 | 30 | 33 | Chart
|
| Inventory days | 2Outside range high inventory days. 2d; 3-period range 1d to 2d. Inventory days: 1.6 days, above normal range; 3-period mean 1.3 days, range 1.1 days-1.5 days. | 1Outside range low inventory days. 1d; 3-period range 1d to 2d. Inventory days: 1.1 days, below normal range; 3-period mean 1.4 days, range 1.2 days-1.9 days. | 1 | 1 | 1 | 1 | 2 | 2 | Chart
|
| Total assets | $400.5m | $374.4m | $355.9m | $339.6m | $330.5m | $334.7m | $355m | $356.6m | Chart |
Reference: annolyse.ai/companies/rad
Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.
These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.
Reported revenue across covered periods.
Like-period revenue growth where comparable.
Company-specific earnings measure where disclosed.
EBITDA-equivalent margin where revenue and earnings are source-backed.
Statutory profit after tax.
Cash generated from operations.
Additional filing-backed metrics for this company. Each point links to the relevant published briefing.
Cash conversion against earnings.
Operating cash flow less capex before leases.
Return on equity.
Borrowings less cash; negative values indicate net cash.
Leverage ratio, suppressed where earnings are not meaningful.
Dividend per share declared for the period.
Dividend payout against statutory NPAT.
Receivables days where the working-capital inputs are source-backed.
Inventory days where the working-capital inputs are source-backed.
Per-period working-capital absorption or release, from the same published history. Positive values are working-capital build; negative values are release.
The setup & the reality
The latest result is checked against what the prior briefing said to watch.
Historical setup
Previous analysisFY26Result releasedAnnolyse analysis published
From PBT rose36.2%; operating cash conversion was 91.8% and capital spending also increased
The arithmetic implies H2 reported EBITDA of NZ$12.5m and reported NPAT of approximately NZ$3.1m. These historical residuals should not be annualised into an underlying earnings forecast. A reconciliation of reported and underlying earnings, together with any forward guidance, is needed to assess FY27 expectations.
Open questions
This briefing cannot assess bed-level occupancy, average resident-day rates or EBITDAR-per-bed trajectory beyond the headline figure, none of which are quantified in the supplied excerpts.
Primary issuer documents used for the HY27 briefing. Document labels are preserved from the publication record; Annolyse does not relabel every financial report as an annual report.
RAD 1H27 Interim Report
HY27 / financial reportRAD 1H27 Investor Presentation
HY27 / results presentationRAD 1H27 Media Release
HY27 / media releaseRAD 1H27 NZX Results Announcement
HY27 / results announcementRAD 1H26 Interim Report
HY26 / financial reportRAD 1H26 Investor Presentation
HY26 / results presentationRAD 1H26 Media Release
HY26 / media releaseRAD 1H26 NZX Results Announcement
HY26 / results announcementRadius Care Annual Report 2026
FY26 / financial reportRAD Upgraded Outlook and 2025 ASM Materials
HY26 / commentaryRAD 2026 ASM Presentation
HY27 / commentaryPeer context
These companies share the same curated sub-sector label. Their reporting definitions can still differ, so compare the underlying measures before ranking them.
Archive
The full chronological archive contains every published result briefing.
HY27 · Released 11 November 2026
Higher statutory profit masks weaker cash generation and less balance-sheet flexibility.
FY26 · Released 13 May 2026
Underlying earnings ran above the historical baseline, but H2 NPAT roughly halved versus H1 as growth-strategy capex stepped up to NZ$16.1m.
HY26 · Released 19 November 2025
A lower effective tax rate flattered NPAT, but EBITDA +41% and leverage cut to 4.3x point to genuine operating gains.
FY25 · Released 21 May 2025
Margin and cash-conversion gains look durable, but a prior-year tax distortion exaggerates the NPAT swing from a $8.5m loss to a $7.0m profit.
HY25 · Released 25 November 2024
Net debt cut 25% and cash conversion improved, but a 94.2% payout sits against a $0.07m cash balance and a higher tax rate.
FY24 · Released 29 May 2024
Operating earnings and leverage improved sharply, but a 335.8% effective tax rate turned PBT of $3.6m into an $8.5m net loss.
Get the next Radius Residential Care result briefing and five-year history updates by email.